153 related articles for article (PubMed ID: 36402300)
1. Molecular and clinical diversity in primary central nervous system lymphoma.
Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
[TBL] [Abstract][Full Text] [Related]
2.
Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
[TBL] [Abstract][Full Text] [Related]
3. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
[No Abstract] [Full Text] [Related]
4. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.
Bruno A; Labreche K; Daniau M; Boisselier B; Gauchotte G; Royer-Perron L; Rahimian A; Lemoine F; de la Grange P; Guégan J; Bielle F; Polivka M; Adam C; Meyronet D; Figarella-Branger D; Villa C; Chrétien F; Eimer S; Davi F; Rousseau A; Houillier C; Soussain C; Mokhtari K; Hoang-Xuan K; Alentorn A
Neuro Oncol; 2018 Jul; 20(8):1092-1100. PubMed ID: 29432597
[TBL] [Abstract][Full Text] [Related]
6. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
[TBL] [Abstract][Full Text] [Related]
7. The genomic and transcriptional landscape of primary central nervous system lymphoma.
Radke J; Ishaque N; Koll R; Gu Z; Schumann E; Sieverling L; Uhrig S; Hübschmann D; Toprak UH; López C; Hostench XP; Borgoni S; Juraeva D; Pritsch F; Paramasivam N; Balasubramanian GP; Schlesner M; Sahay S; Weniger M; Pehl D; Radbruch H; Osterloh A; Korfel A; Misch M; Onken J; Faust K; Vajkoczy P; Moskopp D; Wang Y; Jödicke A; Trümper L; Anagnostopoulos I; Lenze D; Küppers R; Hummel M; Schmitt CA; Wiestler OD; Wolf S; Unterberg A; Eils R; Herold-Mende C; Brors B; ; Siebert R; Wiemann S; Heppner FL
Nat Commun; 2022 May; 13(1):2558. PubMed ID: 35538064
[TBL] [Abstract][Full Text] [Related]
8. Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies.
Hernández-Verdin I; Morales-Martínez A; Hoang-Xuan K; Alentorn A
Curr Opin Neurol; 2022 Dec; 35(6):779-786. PubMed ID: 36367044
[TBL] [Abstract][Full Text] [Related]
9. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
[TBL] [Abstract][Full Text] [Related]
10. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
[TBL] [Abstract][Full Text] [Related]
11. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
Vater I; Montesinos-Rongen M; Schlesner M; Haake A; Purschke F; Sprute R; Mettenmeyer N; Nazzal I; Nagel I; Gutwein J; Richter J; Buchhalter I; Russell RB; Wiestler OD; Eils R; Deckert M; Siebert R
Leukemia; 2015 Mar; 29(3):677-85. PubMed ID: 25189415
[TBL] [Abstract][Full Text] [Related]
12. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
[TBL] [Abstract][Full Text] [Related]
13. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
Zhang Y; Zhou DB
Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898
[TBL] [Abstract][Full Text] [Related]
14. Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors.
Zhong C; Xie T; Chen L; Zhong X; Li X; Cai X; Chen K; Lan S
Front Immunol; 2022; 13():983636. PubMed ID: 36159794
[TBL] [Abstract][Full Text] [Related]
15. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
[TBL] [Abstract][Full Text] [Related]
16. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.
Tateishi K; Miyake Y; Nakamura T; Yamamoto T
Brain Tumor Pathol; 2021 Jul; 38(3):173-182. PubMed ID: 34255226
[TBL] [Abstract][Full Text] [Related]
18. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.
Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
[TBL] [Abstract][Full Text] [Related]
19. Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma.
Heming M; Haessner S; Wolbert J; Lu IN; Li X; Brokinkel B; Müther M; Holling M; Stummer W; Thomas C; Schulte-Mecklenbeck A; de Faria F; Stoeckius M; Hailfinger S; Lenz G; Kerl K; Wiendl H; Meyer Zu Hörste G; Grauer OM
Genome Med; 2022 Sep; 14(1):109. PubMed ID: 36153593
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas.
Choi JS; Nam DH; Ko YH; Seo JW; Choi YL; Suh YL; Ree HJ
Am J Surg Pathol; 2003 Jul; 27(7):919-28. PubMed ID: 12826884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
